483 related articles for article (PubMed ID: 23383209)
1. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1.
Sims JT; Ganguly SS; Bennett H; Friend JW; Tepe J; Plattner R
PLoS One; 2013; 8(1):e55509. PubMed ID: 23383209
[TBL] [Abstract][Full Text] [Related]
2. Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells.
Kanagasabai R; Krishnamurthy K; Druhan LJ; Ilangovan G
J Biol Chem; 2011 Sep; 286(38):33289-300. PubMed ID: 21784846
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin induces atypical NF-κB activation through c-Abl kinase activity in breast cancer cells.
Esparza-López J; Medina-Franco H; Escobar-Arriaga E; León-Rodríguez E; Zentella-Dehesa A; Ibarra-Sánchez MJ
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1625-35. PubMed ID: 23892407
[TBL] [Abstract][Full Text] [Related]
4. Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells.
Ku JM; Kim SR; Hong SH; Choi HS; Seo HS; Shin YC; Ko SG
Mol Cell Biochem; 2015 Nov; 409(1-2):33-43. PubMed ID: 26169986
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Dai Y; Rahmani M; Pei XY; Dent P; Grant S
Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
[TBL] [Abstract][Full Text] [Related]
6. STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.
Huang DY; Chao Y; Tai MH; Yu YH; Lin WW
J Biomed Sci; 2012 Mar; 19(1):35. PubMed ID: 22462553
[TBL] [Abstract][Full Text] [Related]
7. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
[TBL] [Abstract][Full Text] [Related]
8. Zuo Jin Wan reverses P-gp-mediated drug-resistance by inhibiting activation of the PI3K/Akt/NF-κB pathway.
Sui H; Pan SF; Feng Y; Jin BH; Liu X; Zhou LH; Hou FG; Wang WH; Fu XL; Han ZF; Ren JL; Shi XL; Zhu HR; Li Q
BMC Complement Altern Med; 2014 Aug; 14():279. PubMed ID: 25085593
[TBL] [Abstract][Full Text] [Related]
9. Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma.
Chu TS; Chen JS; Lopez JP; Pardo FS; Aguilera J; Ongkeko WM
Arch Otolaryngol Head Neck Surg; 2008 Sep; 134(9):979-84. PubMed ID: 18794444
[TBL] [Abstract][Full Text] [Related]
10. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Wei YL; Liang Y; Xu L; Zhao XY
Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro.
Ferrao PT; Frost MJ; Siah SP; Ashman LK
Blood; 2003 Dec; 102(13):4499-503. PubMed ID: 12881321
[TBL] [Abstract][Full Text] [Related]
12. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
Tseng PH; Lin HP; Zhu J; Chen KF; Hade EM; Young DC; Byrd JC; Grever M; Johnson K; Druker BJ; Chen CS
Blood; 2005 May; 105(10):4021-7. PubMed ID: 15665113
[TBL] [Abstract][Full Text] [Related]
13. Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells.
Cheng Z; Yang N; Liang W; Yan X; Li L; Pan L
Leuk Lymphoma; 2012 Jul; 53(7):1383-9. PubMed ID: 22185283
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
Houghton PJ; Germain GS; Harwood FC; Schuetz JD; Stewart CF; Buchdunger E; Traxler P
Cancer Res; 2004 Apr; 64(7):2333-7. PubMed ID: 15059881
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of c-Abl kinase activity renders cancer cells highly sensitive to mitoxantrone.
Alpay K; Farshchian M; Tuomela J; Sandholm J; Aittokallio K; Siljamäki E; Kallio M; Kähäri VM; Hietanen S
PLoS One; 2014; 9(8):e105526. PubMed ID: 25148385
[TBL] [Abstract][Full Text] [Related]
16. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
17. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
19. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
[TBL] [Abstract][Full Text] [Related]
20. Cytisine exerts anti-tumour effects on lung cancer cells by modulating reactive oxygen species-mediated signalling pathways.
Xu WT; Li TZ; Li SM; Wang C; Wang H; Luo YH; Piao XJ; Wang JR; Zhang Y; Zhang T; Xue H; Cao LK; Jin CH
Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):84-95. PubMed ID: 31852250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
